Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Search Results



Your search returned 1870 record(s).

Page 44 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:


  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
431 18.8 months Hormone-refractory prostate cancer 4 Chemotherapy
University of Athens School of Medicine Greece 1/2004
Treatment Details: Patients: This Phase II study involved 38 patients with hormone refractory prostate cancer. Patients were divided into two groups: Group 1 and Group 2. The average age of patients in Group
 
432 18.8 months metastatic breast cancer 4 Biologic therapy
Chemotherapy
University of Munich Germany 12/2005
Treatment Details: Patients: This Phase II study involved 20 women with HER2-overexpressing metastatic breast cancer. All patients received chemotherapy before the study. The median age was 52.5 years. Meta
 
433 18.8 months Advanced, Recurrent Ovarian Cancer 4 Chemotherapy
University General Hospital of Heraklion Greece 4/2014
Treatment Details: Patients: This phase 2 study involved 23 advanced, platinum-sensitive, recurrent ovarian cancer patients who had been previously treated. The median patient age was 62.0 years. Treatmen
 
434 18.8 months Epithelial ovarian cancer 4 Chemotherapy
University General Hospital Attikon Greece 7/2010
Treatment Details: Patients: This study involved 45 women with epithelial ovarian cancer who had relapsed following previous treatment with carboplatin and paclitaxel. The median patient age was 60 years.
 
435 18.7 months Metastatic hormone-refractory prostate cancer 3 Chemotherapy
Gene Therapy
Vancouver Cancer Centre Canada 12/2001
Treatment Details: Patients: This Phase I dose-finding study involved 26 patients with metastatic hormone-refractory prostate cancer. The median age was 69 and the median PSA was 135 (ranged from 30-860). Si
 
436 18.7 months colorectal (metastatic) 4 Chemotherapy
Hopital Huriez (CHRU) France 3/2006
Treatment Details: Patients: This Phase II trial involved a total of 39 patients with metastatic colorectal cancer. For 29 patients the site of the primary tumor was in the colon. For 9 patients it was in th
 
437 18.7 months colorectal (metastatic) 4 Chemotherapy
Hopital Huriez (CHRU) France 3/2006
Treatment Details: Patients: This Phase II trial involved a total of 39 patients with metastatic colorectal cancer. For 29 patients the site of the primary tumor was in the colon. For 9 patients it was in th
 
438 18.7 months Hormone-refractory prostate cancer 4 Chemotherapy
University Hospital Hamburg-Eppendorf Germany 1/2006
Treatment Details: Patients: This Phase II study involved 34 men with hormone refractory prostate cancer. The median age was 67 years. Previous therapies included surgery (13 patients), radiation (24), and e
 
439 18.6 months metastatic melanoma 4 Chemotherapy
Immunotherapy
Tel Aviv-Sourasky Medical Center Israel 2/2006
Treatment Details: Patients: This phase II study involved 23 patients with advanced inoperable melanoma, none of whom had been exposed to previous chemotherapy. Patients included 14 men and 9 women with the m
 
440 18.6 months Metastatic colorectal cancer 4 Biologic therapy
Chemotherapy
Unità Operativa di Oncologia e Ematologia, Istituto Clinico Humanitas Italy 11/2008
Treatment Details: Patients: This phase 2 study involved 100 patients with metastatic colorectal cancer. Their ages ranged from 41 to 78 years. Most (over 80%) had previously received treatment with surgery.
 
Page 44 of 187  | Previous Page  | Next Page